Chemotherapy (preferably with a single chemotherapeutic agent) combined with capecitabine (including capecitabine monotherapy: when the preferred drug identified is capecitabine alone). for cholangiocarcinoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Dec 2025: Trial registered, NCT07296666

The trials

NCT07296666: Adjuvant Chemotherapy for BTC Based on 3D-PTA

State
Not started
Phase
Phase 2
People
98 planned
Started
Dec 2025
Primary completion
Oct 2027
Arms
Treatment group: Capecitabine + 3D-PTA-selected chemotherapy drugs (conventional dosage)
Results
None posted
  1. 22 Dec 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.